Orphan drugs’ financial success raises questions
pharmaphorum
JUNE 2, 2022
And of course, in many cases, these drugs have higher than average price tags compared to the wider market which is due to the limited – or in most cases – non-existent competition within a treatment area.”. Raising questions. While in the US, Congress has proposed limits to the Orphan Drug Tax Credit, as part of the Build Back Better Act.
52 
Let's personalize your content